General Medical Dermatology

“Over time, I’ve realized that being a happy doctor isn’t just about the science, it is also about having the skills and tools to lead with purpose, to feel fulfilled and to make a real impact.”   LEADderm ...

Money is something we all have to navigate, but it is not always something we are taught to understand or manage, nor necessarily something we connect with building a fulfilling career in medicine. In the second episode of our LEADderm mini-series, we are joined by two US-based clinicans: dermatologist and LEADderm Founder Dr Jennifer Soung, and Dr Bonnie Koo, Founder of Wealthy Mom MD and author of Defining Wealth for Women: Peace, Purpose, and Plenty of Cash, for an honest conversation about financial confidence and redefining wealth. Together, we explore how shifting our mindset around money can create greater freedom, choice and resilience, helping healthcare professionals feel more grounded so that they can thrive in their clinical careers and beyond.

At the recent ILDS World Skin Summit, dermatology leaders from across the globe came together to discuss the evolving role of skin health in global medicine. In this interview, Prof. Olivier Gaide explores what sets the meeting apart from traditional scientific congresses and reflects on the key highlights from this year’s summit.

As 2025 draws to a close, it is clear that the past year has brought notable shifts across dermatology. To reflect on the developments that stood out most, members of our editorial board and recipients of our 2025 Future Leaders in Dermatology award share their perspectives, drawing on experience across subspecialties, regions and stages of career.

Early phase pooled results from 32 patients indicate that lonvoguran ziclumeran, a CRISPR-based gene-editing therapy, achieved durable, one-time disease control in hereditary angioedema (HAE). The phase 1/2 data demonstrated deep and sustained reductions in plasma kallikrein levels, with most patients remaining attack-free and prophylaxis-free for up to three years and a safety profile consistent with earlier findings.

Roflumilast 0.3% foam, a highly potent PDE4 inhibitor, represents a major advance in the management of seborrhoeic dermatitis. Approved by the FDA in 2023 following the phase 3 STRATUM trial, the once-daily, non-steroidal foam demonstrated significant improvements in signs and symptoms of the disease. At the EADV Congress 2025, Dr Raj Chovatiya presented new subgroup data showing the treatment’s consistent efficacy and tolerability across diverse skin and hair types.

Dermatologists play a vital role in creating safe, inclusive spaces for LGBTQIA+ patients. In this interview, Assistant Professor Teerapong Rattananukrom explores why inclusive language matters, the unique skin challenges faced by transgender individuals, and how greater representation in research can help shape more equitable, compassionate care.

Skin neglected tropical diseases (NTDs), including leprosy, lymphatic filariasis and onchocerciasis, remain a significant public health challenge in many low- and middle-income countries. Frontline healthcare workers often struggle to recognise and manage these conditions due to limited diagnostic tools and gaps in specialist training. In this interview, we speak with Dr Olufolakemi Cole-Adeife (Lagos, Nigeria) about a virtual training programme designed to overcome these barriers.

Epidermal differentiation disorders (EDDs) are a group of inherited skin conditions caused by disruptions in epidermal development. In recent years, the field has seen major progress, with significant updates to nomenclature, classification and their management. To gain deeper insight into these developments, we spoke with Dr Antoni Gostyński (Maastricht, Netherlands), who co-chaired the EADV 2025 session ‘Epidermal Differentiation Disorders (EDDs) Group: From Genes to Clinics – The Truth About EDDs in 90 Minutes’.